MA47290A - Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée - Google Patents

Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée

Info

Publication number
MA47290A
MA47290A MA047290A MA47290A MA47290A MA 47290 A MA47290 A MA 47290A MA 047290 A MA047290 A MA 047290A MA 47290 A MA47290 A MA 47290A MA 47290 A MA47290 A MA 47290A
Authority
MA
Morocco
Prior art keywords
agonist
2rbeta
selective
action
combination
Prior art date
Application number
MA047290A
Other languages
English (en)
Inventor
Deborah Charych
Peter Kirk
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA47290A publication Critical patent/MA47290A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA047290A 2015-10-08 2016-10-07 Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée MA47290A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562239207P 2015-10-08 2015-10-08

Publications (1)

Publication Number Publication Date
MA47290A true MA47290A (fr) 2019-11-27

Family

ID=57249859

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047290A MA47290A (fr) 2015-10-08 2016-10-07 Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée

Country Status (12)

Country Link
US (1) US20180296645A1 (fr)
EP (1) EP3359182B1 (fr)
JP (3) JP7407511B2 (fr)
KR (1) KR20180063184A (fr)
CN (1) CN108135978A (fr)
AU (1) AU2016335860B2 (fr)
CA (1) CA3000211A1 (fr)
HK (1) HK1253347A1 (fr)
IL (1) IL258456B (fr)
MA (1) MA47290A (fr)
MX (1) MX2018004296A (fr)
WO (1) WO2017062832A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
WO2020247388A2 (fr) 2019-06-03 2020-12-10 Medikine, Inc. Composés de liaison de sous-unité de récepteur il-2alpha
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
ES2240972T3 (es) * 1993-11-12 2005-10-16 Gilead Sciences, Inc. Mutantes de la trombina.
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP4560629B2 (ja) * 2005-03-31 2010-10-13 国立大学法人 筑波大学 腫瘍壊死誘導療法の抗腫瘍効果増強剤
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
KR101304157B1 (ko) 2005-06-16 2013-09-06 넥타르 테라퓨틱스 분해가능한 결합을 갖는 컨주게이트 및 이러한 컨주게이트제조에 유용한 고분자 시약
WO2007071388A1 (fr) * 2005-12-21 2007-06-28 Sentoclone Ab Methode amelioree pour la proliferation de lymphocytes t reactifs a une tumeur a des fins d'immunotherapie pour des patients atteints de cancer
NZ577397A (en) 2006-12-27 2012-01-12 Nektar Therapeutics Factor ix moiety-polymer conjugates having a releasable linkage
WO2009135031A1 (fr) * 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Il-15 substitué
RS61854B1 (sr) * 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
EP3134123B1 (fr) * 2014-02-21 2021-02-17 Nektar Therapeutics (India) Pvt. Ltd. Agonistes sélectifs d'il-2rbêta en combinaison avec un anticorps anti-ctla-4 ou un anticorps anti-pd-1
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère

Also Published As

Publication number Publication date
KR20180063184A (ko) 2018-06-11
EP3359182B1 (fr) 2023-04-19
WO2017062832A1 (fr) 2017-04-13
JP7407511B2 (ja) 2024-01-04
CA3000211A1 (fr) 2017-04-13
CN108135978A (zh) 2018-06-08
JP2018530568A (ja) 2018-10-18
AU2016335860B2 (en) 2023-08-10
IL258456B (en) 2021-07-29
US20180296645A1 (en) 2018-10-18
HK1253347A1 (zh) 2019-06-14
EP3359182A1 (fr) 2018-08-15
MX2018004296A (es) 2018-08-01
IL258456A (en) 2018-06-28
JP2021066748A (ja) 2021-04-30
AU2016335860A1 (en) 2018-04-12
JP2023099731A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
MA46180A (fr) Analogues de l'amyline
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
MA49905A (fr) Polyesteramines et polyesterquats
MA49006A (fr) Inhibiteurs d'ip6k
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3321216T3 (da) Pendullager
DK3328395T3 (da) Ny brug af dextransulfat
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
MA47290A (fr) Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
FI20145984A (fi) Substituoitua bentsofurokinolitsiinia ja ɑ2-adrenergista agonistia käsittävät koostumukset
DK3562921T3 (da) Smøremiddelsammensætning indbefattende n-alkyleret dianilin
MA44152A (fr) Raccord antisismique doté d'un trou oblong
ZA201901089B (en) S1p1 agonist and application thereof
DE112018006116A5 (de) Reibteil
DK3706699T3 (da) Badekonstruktion
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser
ES1148033Y (es) Dispositivo de atraccion y retencion de la mosca del olivo
ES1158189Y (es) Mosquetón con anclaje magnético integrado
IT201700103032A1 (it) Moschettone
FR3087334B1 (fr) Cage interosseuse
FI11581U1 (fi) Lattiakaivon sisäosa ja lattiakaivo
IT201700090331A1 (it) "lopemide"